The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia

Maria I. Edilova,<sup>1</sup>\* Jaclyn C. Law,<sup>1</sup>\* Safoura Zangiabadi<sup>2</sup>, Kenneth Ting<sup>1</sup>, Achire N. Mbanwi<sup>1</sup>, Andrea Arruda,<sup>3</sup> David Uehling,<sup>4</sup> Methvin Isaac, <sup>4</sup> Michael Prakesch,<sup>4</sup> Rima Al-awar,<sup>4,5</sup> Mark D. Minden,<sup>3</sup> Ali A. Abdul-Sater<sup>2</sup>\*\* and Tania H. Watts<sup>1</sup>\*\*

- 1. Department of Immunology, University of Toronto, Toronto, ON, Canada
- 2. School of Kinesiology and Health Science, Muscle Health Research Centre (MHRC), Faculty of Health, York University, Toronto, ON, Canada.
- 3. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- 4. Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada
- 5. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada

Running title: Targeting the PKN1-TRAF1 signaling axis in CLL

\*Co-first authors. \*\*Co-senior authors.

Corresponding author: Tania H. Watts, Department of Immunology, University of Toronto, Toronto, ON, Canada M5S 1A8; tel: 416-978-4551; tania.watts@utoronto.ca

#### Abstract

TRAF1 is a pro-survival adaptor molecule in TNFR superfamily (TNFRSF) signaling. TRAF1 is overexpressed in many B cell cancers including refractory chronic lymphocytic leukemia (CLL). Little has been done to assess the role of TRAF1 in human cancer. Here we show that the protein kinase C related kinase Protein Kinase N1 (PKN1) is required to protect TRAF1 from cIAP-mediated degradation during constitutive CD40 signaling in lymphoma. We show that the active phospho-Thr774 form of PKN1 is constitutively expressed in CLL but minimally detected in unstimulated healthy donor B cells. Through a screen of 700 kinase inhibitors, we identified two inhibitors, OTSSP167 and XL-228, that inhibited PKN1 in the nanomolar range and induced dose-dependent loss of TRAF1 in RAJI cells. OTSSP167 and XL-228 treatment of primary patient CLL samples led to a reduction in TRAF1, pNF-κB p65, pS6, pERK, Mcl-1 and Bcl-2 proteins, and induction of activated caspase-3. OTSSP167 synergized with venetoclax in inducing CLL death, correlating with loss of TRAF1, Mcl-1 and Bcl-2. Although correlative, these findings suggest the PKN1-TRAF1 signaling axis as a potential new target for CLL. These findings also suggest OTSSP167 and venetoclax as a combination treatment for TRAF1 high CLL.

#### Introduction

CLL is the most common human leukemia with an estimated 21,040 new cases and 4060 deaths in the US in 2020 (https://seer.cancer.gov/statfacts/html/clyl.html). CLL is considered to be largely a disease of the lymph node and bone marrow, where CLL cells receive survival signals through their B cell receptor (BCR).<sup>1, 2</sup> Several promising new therapies for CLL target BCR signaling or cell survival, including the phosphatidyl inositol-3-kinase inhibitor idelalisib, the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, as well as the Bcl-2 antagonist venetoclax.<sup>3-8</sup> While these treatments are showing great promise, responses are not always durable and when relapse occurs there are limited treatment options available.<sup>3, 9, 10</sup>

In addition to signaling through the BCR, B cells require signals through TNFRSF members such as CD40, which activates NF-kB to induce pro-survival Bcl-2 family members.<sup>11</sup> Many human malignancies including CLL, B cell lineage non-Hodgkins lymphoma and Burkitt's lymphomas, exhibit constitutive signaling via TNFRs, such as CD40, CD30 or the EBV protein LMP1.<sup>12-14</sup> TNFRSF members trigger NF- $\kappa B$  activation through recruitment of TRAF proteins.<sup>15</sup> TRAF1 is an NF- $\kappa B$  inducible protein<sup>16</sup> that on its own cannot induce NF-κB but as a 1:2 heterotrimer with TRAF2 recruits a single cellular inhibitor of apoptosis protein (cIAP)<sup>17</sup> to induce activation of the classical NF-kB signaling pathway downstream of several TNFRSF members, including CD40 on B cells.<sup>18</sup> cIAPs are dual function E3 ligases. cIAPs can add K63-linked polyubiquitin to RIP, thereby activating NF-KB signaling,<sup>19</sup> but can also add K48- linked ubiquitin to TRAF proteins, thereby inducing TRAF protein degradation.<sup>20</sup> Thus an outstanding question is how TRAF proteins can recruit cIAPs without being degraded. TRAF1 is overexpressed in 48% of B cell related cancers with the highest expression in the most refractory CLL.<sup>21</sup> Non-coding single nucleotide polymorphisms in TRAF1 have been linked to non-Hodgkin's lymphoma;<sup>22</sup> however, TRAF1 dependent signaling has not been specifically targeted as a cancer therapy. While TRAF2, the binding partner for TRAF1 is ubiquitously expressed and mice deficient in TRAF2 die of lethal inflammation,<sup>23</sup> TRAF1 expression is largely limited to cells of the immune system<sup>24</sup> and mice lacking TRAF1 have no overt phenotype.<sup>25</sup> The finding that *Traf1* is required for lymphomagenesis in a spontaneous mouse tumor model induced by constitutively active NF- $\kappa$ B2<sup>26</sup> makes TRAF1 a potential target in B cell malignancies; however, signaling adaptors are not readily amenable to drug discovery.

TRAF1 is a target of phosphorylation by the ubiquitously expressed protein kinase C related kinase PKN1 (also known as PRK1).<sup>27</sup> PKN1 phosphorylates TRAF1, but not other TRAF family members, at serine 146 in human or serine 139 in mouse.<sup>27</sup> Here we show that phosphorylation of TRAF1 S146 by PKN1 is required to protect TRAF1 from cIAP-mediated degradation during constitutive CD40 signaling in RAJI cells. We find that the activated phospho-Thr744 form of PKN1 is readily detected in patient CLL cells but minimally present in B cells from healthy donors. Accordingly, we screened a library of 700 kinase inhibitors and identified two PKN1 inhibitors, OTSSP167, a maternal embryonic leucine zipper kinase (MELK) inhibitor and XL-228, a multi-targeted tyrosine kinase inhibitor, that induced dose-dependent decreases in TRAF1, NF-κB p65, pERK, pS6, Mcl-1 and Bcl-2 proteins in primary patient CLL cells, with concomitant induction of cell death. We also report that OTSSP167 has synergistic effects with the Bcl-2 antagonist venetoclax in inducing cell death.

#### Methods

**Human subjects.** Frozen peripheral blood mononuclear cells (PBMCs) from 25 CLL patients were obtained from the Leukemia Tissue Bank at Princess Margaret Cancer Centre/University Health Network (UHN), Toronto, Ontario (**Table S1**). Informed consent for tissue bank donation was in compliance with the Declaration of Helsinki and in agreement with the UHN Research Ethics Review Board (protocol 01-0573) and the research herein was also approved by the University of Toronto Research Ethics board (Protocol #: 00030910). Cytogenetic alterations in CLL samples were determined by fluorescent *in situ* hybridization. Researchers were blinded to the clinical status of the patient samples until study completion. CLL cells were identified as CD19<sup>+</sup>/CD5<sup>+</sup> cells by flow cytometry and generally accounted for >85% of PBMC. Blood from healthy donors was obtained with informed consent (University of Toronto REB protocol number 00027673) and samples stored as frozen PBMC until use. Healthy donor B cells were purified from PBMC using the EasySep Human B cell Isolation Kit (STEMCELL Technologies) according to the manufacturer's protocol.

Cell lines. RAJI and Daudi cell lines were from ATCC, 293 cells from in Invitrogen. For further details on cell culture and procedures see supplemental methods. The human embryonic kidney 293 cell line (293 FT) was obtained from Invitrogen (Invitrogen, Carlsbad, United States) and cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, United States) supplemented with 10% Fetal Calf Serum (FCS, Thermo Fisher Scientific) and 1% of 100X Glutamine-Penicillin-Streptomycin (GPPS) (Sigma-Aldrich, Oakville, Canada). RAJI and Daudi were obtained from the ATTC and maintained in RPMI 1640 with FCS/GPPS. All cell lines tested negative for mycoplasma (Mycoplasma detection kit, Millipore-Sigma, Oakville, Ontario). OP9 cells were kindly provided by J.C. Zuniga-Pflücker, Sunnybrook research institute, Toronto, Canada and plated  $10^5$  cells/well of a 24-well plate in  $\alpha$ -MEM supplemented with 20% FCS and GPPS and used when confluent.

**Plasmid construction and transfection**. The human TRAF1 ORF was amplified from RAJI cells cDNA, cloned into pENTR-D-TOPO vector (Invitrogen) and the S146A mutation introduced into pENTR-D-TOPO using QuikChange II Site-Directed Mutagenesis Kit (Stratagene, San Diego, United States) following manufacturer's instructions. WT-TRAF1 and S146A-TRAF1 were cloned into a pcDNA3-c-Flag vector, a gift from Stephen Smale (Addgene plasmid # 20011). The Flag tag in WT-TRAF1 construct was replaced with a 3x-HA tag. WT and K644E human PKN1 ORFs were codon optimized for mammalian gene expression and synthesized by GeneArt Gene Synthesis (Invitrogen). WT and K644E PKN1 were the cloned into pCDNA3.1+ (Invitrogen). Cells were transfected with either 200ng of WT-TRAF1-HA, 200ng of S146A-TRAF1-FLAG, 50ng of WT PKN1, 50ng of K644E-PKN1 or 50ng of PCDNA 3.1+ empty vector with 1.5µl/well of Lipofectamine 2000 following manufacturer's instructions (Invitrogen). After 6h of incubation, the media was then replaced with fresh growth medium and cells were cultured overnight until cycloheximide treatment on the next day.

**shRNA knockdown.** 3x10<sup>6</sup> 293FT cells were transfected with 0.8µg of VSV-G, 5.4µg psPAX2, and 6µg of pLKO.1-shRNA plasmid (Openbiosystems, Chicago, United States) using lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. shRNA mature antisense sequences for TRAF1 and PKN1 are AACAATGTTCTCAAACACACG and TATCCGCTTCTCACACATCAG, respectively. 60h after transfection, the supernatant of the cultures was collected, filtered through a low protein binding 0.22µM filter, and added to target cells for 24h before selection with 4µg/ml puromycin (Bio Basic, Markham, Canada). For TRAF1 knockdown in RAJI cells, cells were then seeded in 96 wells at 1 cell per well, allowing cells to grow into clones from a single cell. Several clones were then tested for reduction in TRAF1 levels by Western Blotting and Flow cytometry, and those with the lowest TRAF1 levels were chosen for downstream assays. For PKN1 knockdown in RAJI and 293T cells, sufficient reduction in PKN1 protein level was observed in the pool knockdown by Western blotting so no cloning was necessary.

**Cycloheximide Inhibition and Western blot.** Following overnight recovery from transfection, 293FT or RAJI cells were treated or not with cycloheximide (Sigma-Aldrich) at 3µg/ml as indicted in the figures. After treatment, the media was removed and cells were washed once with PBS (Sigma-Aldrich), then lysed for protein extraction. Where indicated, SMAC mimetic BV6 (Sigma-Aldrich, St. Louis, USA) was added at 5µM. Cells were lysed in 0.5% Nonidet P-40 (Millipore-Sigma, Oakville, Canada) with phosphatase and protease inhibitor mix (Roche, Basel, Switzerland). Total protein concentration was quantified by a colorimetric assay (Bio-Rad, Berkeley, United States), then subjected to SDS-PAGE (10% gel) and transferred to polyvinylidene difluoride membranes (semi-dry transfer; Bio-rad).After blocking, membranes were probed with antibodies specific for TRAF1 (clone 45D3, Cell Signaling, Danvers, United States), PKN1 (BD Biosciences, Franklin Lakes New Jersey, United States) and GAPDH (Thermo Fisher Scientific), followed by HRP-conjugated anti-rabbit or anti-mouse (Jackson Immunoresearch, Baltimore, United States), and signals were detected with a chemiluminescence substrate (GE Healthcare, Baie D'Urfe, Quebec, Canada) and visualized by autoradiography.

**Immunoprecipitation.**  $6x10^6$  RAJI cells in 10cm dishes were treated with Cycloheximide (see above) with or without BV6 and lysed in 800 µl 1% NP-40 buffer including protease and phosphatase inhibitor cocktails. 20 µl prewashed magnetic Protein G Dynabeads (Thermofisher) were incubated with 0.5 µg antibody for CD40 (IP1; G28.5, purified from hybridoma cell line using Protein G sepharose, hybridoma was originally provided by Diane Hollenbaugh, then at Bristol-Myers Squibb; the antibody is now available at BioXCell) for 10min at room temperature, washed and then incubated with 100 µl of lysates overnight at 4  $^{\circ}$ C. Unbound proteins were saved for a subsequent immunoprecipitation (IP2) by incubating them with 20 µl prewashed magnetic Protein G Dynabeads (Thermofisher) for 10min at room temperature and 0.5 µg antibody for TRAF1 (clone 1F342; Serviceeinheit Monoklonale Antikörper; Institut für Molekulare Immunologie, Munich, Germany). After three washes, immunoprecipitated proteins from IP1 and IP2 were fractionated on a 10% SDS-PAGE and immunoblotted for TRAF1 (clone 45D3; Cell Signaling).

**Kinase screen.** A screen of the 700 kinase Ontario Institute for Cancer Research (OICR) inhibitor library at 1 $\mu$ M concentration on PKN1 kinase activity *in vitro* was conducted by contract research organization Eurofins as described on their website (www.eurofins.com). Briefly, PKN1 is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250  $\mu$ M KKLNRTLSFAEPG, 10 mM magnesium acetate and gamma-<sup>33</sup>P-ATP. The reaction is initiated by the addition of the Mg/ATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of phosphoric acid to a concentration of 0.5%. 10 ul of the reaction is then spotted onto a P30 filtermat and washed four times for 4 minutes in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting. The kinase inhibitor library (**Table S2**) is an expanded version of one we have used previously<sup>28, 29</sup> and is comprised both of clinically investigated or marketed agents, as well as pre-clinical compounds identified from the patent and primary literature. Of the 700 kinases screened, 28 were selected for further dose titration (**Table S3**). Of the 28 screened *in vitro* by Eurofins, 9 were selected for further testing on RAJI cells (**Table S4**). Inhibitors were added in a final concentration of 0.1% DMSO in complete media and TRAF1 was measured by intracellular flow cytometry at 24hrs. Known targets of these drugs and IC<sub>50</sub> for inhibition of PKN1 kinase activity *in vitro* are included in **Table S3 and S4**.

**Treatment of RAJI cells with inhibitors and flow cytometry analysis.** shCTL, shTRAF1 and shPKN1 RAJI cell lines, were seeded at 2x10<sup>5</sup> cells per well in a 48-well plate in complete media (RPMI 1640 with added 10% Fetal Calf Serum (FCS), 2-ME, glutamine, penicillin, streptomycin and non-essential amino acids). Cells were harvested for flow cytometric analysis after 24h of treatment with 0.1% DMSO control, PF-941222<sup>30</sup>, UNC-2025 (Selleckchem, Houston, USA), crenolanib (Selleckchem), ipatasertib (Selleckchem), tofacitinib (Selleckchem), AT7867 (Selleckchem), uprosertib (Selleckchem), XL-228 (Chemietek, Indianapolis, USA), or OTSSP167 (Selleckchem), at various concentrations. All RAJI cells

were treated with inhibitors in a final concentration of 0.1% DMSO in complete media. For analysis by flow cytometry, Fc receptors were blocked with human Fc Block (eBioscience). For surface staining, cells were stained with eBioscience Fixable Viability Dye eFluor® 506 and then fixed for intracellular staining with Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Purified TRAF1 antibody (clone 1F3, Serviceeinheit Monoklonale Antikörper; Institut für Molekulare Immunologie, Munich, Germany) was used prior to secondary staining with goat anti-rat PE (clone poly4054, Biolegend) for TRAF1.

**OP9 co-culture, CLL samples and treatment with inhibitors**. OP9 cells were re-suspended at  $10^5$  cells/mL in OP9 Media ( $\alpha$ -MEM with added 20% FCS, glutamine, penicillin and streptomycin) and seeded at  $5x10^4$  cells per well into a 24-well plate. CLL patient samples were thawed and re-suspended at  $8x10^6$  cells/mL in high glucose complete media (complete media with added 2.5g/L total glucose), plated at  $2x10^6$  cells per well on a 24-well plate containing confluent OP9 and rested overnight. Samples were collected for flow cytometric analysis after 24h of treatment with 0.1% DMSO control or OTSSP167 or XL-228 or Venetoclax (EnzoLife Sciences, Farmingate, NY, ordered through Cedarlane, Ontario, Canada) at various concentrations. All CLL cells were treated with inhibitors in a final concentration of 0.1% DMSO in high glucose complete media.

### Flow cytometry analysis of patient samples.

*Bcl-2 family members and TRAF1.* Anti-human Fc Block was used to block Fc receptors. For surface staining, live cells were stained with Fixable Viability Dye eFluor® 506. CLL cells were surface stained with anti-CD19 BV605 (clone HIB19) from Biolegend (San Diego, CA) and CD5 PE-Cy7 (clone UCHT2) purchased from eBioscience (La Jolla, CA). For intracellular staining, cells were fixed and permeabilized using Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Purified TRAF1 antibody, anti-human Bcl-2 BV421 (clone 100, Biolegend) and anti-human Mcl-1 Alexa Fluor 647 (clone D2W9E, New England Biolabs) were used prior to secondary staining with goat anti-rat PE for TRAF1.

*Phosphomarkers.* For phosphoflow, live cells were stained with Fixable Viability Dye eFluor® 506 for 10min at 37°C prior to adding one volume of 2X Cytofix/Perm/Wash Buffer (3% PFA + 2X BD Perm/Wash + ddH<sub>2</sub>0) directly to cell culture and incubated at room temperature for 15min and on ice for 1h. Cells were washed twice with Perm/Wash buffer (BD Biosciences) and re-suspended in Perm/Wash buffer with anti-human Fc blocking antibody. Cells were then stained with anti-CD19 BV605, anti-CD5 PE-Cy7, anti-human pNF $\kappa$ Bp65-eFluor 660 (clone B33B4WP), anti-pS6 PE (clone cupk43k) and anti-pERK PerCP-eF710 (clone MILAN8R) from eBioscience for 1h at room temperature.

*Cleaved caspase-3 and TRAF1.* Anti-human Fc Block was used to block Fc receptors and then surface stained with Fixable Viability Dye eFluor® 506, anti-CD19 BV605 and anti-CD5 PE-Cy7. For intracellular staining, cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set. Purified TRAF1 antibody and anti-cleaved caspase-3 Alexa Fluor 647 (clone D3E9, CST) were used prior to secondary staining with goat anti-rat PE (clone poly4054, Biolegend) for TRAF1. Gating on live cells was excluded when analysing cleaved caspase-3<sup>+</sup> cells.

Data were acquired on a BD LSRFortessa<sup>TM</sup> X-20 flow cytometer and analyzed using FlowJo v10.7.1 software. Protein expression by flow cytometry is quantified as the median fluorescence intensity (MFI) of the specific antibody stain minus the fluorescence minus one (FMO; background) control, which is referred to as "dMFI". Statistics were calculated using Prism GraphPad v8 software. Researchers were blind to patient demographics and clinical data until experimental data acquisition and analysis was complete.

**Data availability statement:** Complete gels and raw flow cytometry FCS files associated with the figures are available from the authors upon request.

#### 1 Results

# 2

# 3 *PKN1 is required for TRAF1 protein stability*4

5 To determine the effect of PKN1 on TRAF1 biology, we knocked down PKN1 in lymphoma cell lines using 6 lentiviral delivery of either a control small hairpin (sh) RNA (shCTL) or an shRNA targeting PKN1 7 (shPKN1). Unexpectedly, knockdown of PKN1 led to a concomitant reduction in the level of TRAF1 8 protein in RAJI and Daudi cells (Figure 1A). To test whether PKN1 affected protein stability, RAJI cells 9 expressing control shRNA (shCTL) or shRNA targeting PKN1 (shPKN1) were incubated with 10 cycloheximide at 37°C to block new protein synthesis and analyzed for levels of PKN1 and TRAF1 by western blotting. The results show that the absence of PKN1 is associated with decreased stability of 11 12 TRAF1 protein (Figure 1B).

13

PKN1 was previously shown to phosphorylate TRAF1 on serine 146.<sup>27</sup> To determine if the phosphorylation 14 15 of TRAF1 S146 by PKN1 is responsible for TRAF1 stability, we generated a mutant human TRAF1 construct in which serine 146 was replaced with alanine (S146A). 293 cells were chosen for this experiment 16 as they do not express TRAF1.<sup>31</sup> Upon transient transfection into 293T cells, TRAF1 S146A showed 17 18 reduced stability compared to WT TRAF1 (Figure 1C). In contrast, when TRAF1 WT or S146A were 19 expressed in 293T cells in which PKN1 had been knocked down by shRNA, both WT and TRAF1S146A 20 showed a similar half-life, which was decreased compared to that of WT TRAF1 in PKN1 sufficient cells 21 (Figure 1D).

22

23 To test whether the kinase activity of PKN1 was required for TRAF1 stability, we expressed TRAF1 as well as shRNA-resistant WT or kinase dead (K644E) PKN1<sup>32</sup> in 293T cells that had been stably transduced 24 with shPKN1 (Figure 1E). In the absence of PKN1, TRAF1 protein showed a half-life of between 2 and 25 26 4h. Overexpression of WT PKN1 in the PKN1 knockdown cells increased the TRAF1 protein half-life to 27 at least 6h. In contrast, kinase dead PKN1 failed to increase TRAF1 stability. Although we observed higher 28 expression of WT compared to kinase dead PKN1 in 293T cells, the level expressed was still in excess of 29 the physiological level of PKN1 observed in cells before knockdown. Moreover, in another experiment, 30 supraphysiological levels of kinase dead PKN1 also failed to increase TRAF1 stability (data not shown). 31 Thus, reduced expression of PKN1 K644E is unlikely to account for its lack of efficacy in conferring 32 TRAF1 protein stability. The finding that WT but not K644E PKN1 restores TRAF1 stability argues against 33 off-target effects of PKN1 knockdown. Taken together, these results show that phosphorylation of TRAF1 34 by PKN1 on S146 is required for TRAF1 protein stability in a B cell lymphoma.

35 36

37 *PKN1 protects TRAF1 from cIAP-mediated degradation in the CD40 signaling complex* 

38

39 TRAF1 is important for the recruitment of cIAPs leading to NF-κB activation. However, cIAPs can add 40 K48-linked ubiquitin to TRAF proteins, thereby inducing TRAF protein degradation.<sup>20</sup> Therefore, we hypothesized that PKN1 is required to protect TRAF1 from cIAP mediated degradation during CD40 41 42 signaling. SMAC mimetics inhibit cIAP function by inducing their autoubiquitination and degradation.<sup>33</sup> 43 To test the role of cIAPs in TRAF1 degradation, RAJI cells were treated with cycloheximide with or without 44 the SMAC mimetic BV6 and then CD40 was immunoprecipitated from control RAJI cells or from RAJI 45 cells knocked down for PKN1. A second immunoprecipitation of TRAF1 was used to analyze the effect of 46 SMAC mimetics on the cytosolic, non-CD40 associated TRAF1 pool. In the presence of PKN1, CD40 47 associated TRAF1 protein was decreased at 6h, but rescued by BV6 (Figure 2A). In the absence of PKN1, 48 TRAF1 was less stable, already degrading by 3h, and again partially rescued by BV6 treatment. In contrast, 49 the cytosolic pool of TRAF1 (IP2 in Figure 2A) was not sensitive to BV6 treatment. These results show 50 that cIAPs contribute to degradation of TRAF1 in the CD40 signaling complex, and that PKN1 partially 51 protects TRAF1 from cIAP-induced degradation.

52 53

### TRAF1 and PKN1 contribute to constitutive MAPK and mTOR signaling in RAJI cells

We next asked whether PKN1 and TRAF1 contribute to constitutive signaling in RAJI cells. RAJI cells
were deprived of serum and amino acids and then serum / amino acids were added back to synchronize
constitutive signaling. Knockdown of TRAF1 reduced the level of pErk1/2 and pS6, a downstream target
of mTOR (Figure 2B). Knockdown of PKN1 had an intermediate effect compared to direct TRAF1
knockdown, correlating with its partial effect on TRAF1 levels (see Figure 1A). These findings suggested
that inhibition of PKN1 could be used to reduce constitutive TRAF1-dependent survival signaling in B cell
cancers.

62

# *Identification of PKN1 inhibitors that reduce TRAF1 among the OICR library of 700 kinase inhibitors*

65 The above findings showed that PKN1 is important for TRAF1 protein stability. Therefore, it was of interest 66 to identify a PKN1 inhibitor that could be used to test the importance of PKN1 in primary unmanipulated 67 patient samples. To this end, we conducted a screen of the Ontario Institute for Cancer Research (OICR) 68 kinase inhibitor library, which consists of 700 known kinase inhibitors. After an initial screen of inhibitors 69 at 1µM (Table S2), 28 kinase inhibitors that substantially inhibited PKN1 were subjected to further dose-70 response analysis (Table S3). Of these compounds, we chose 9 that inhibited PKN1 in vitro in the 11-50nM 71 range to test for effects on lowering TRAF1 in RAJI cells. The other known targets and IC<sub>50</sub> for PKN1 72 inhibition for these compounds are listed in **Table S4**. The choice of compounds for testing on RAJI was 73 made to avoid compounds for which known off target effects make them likely to decrease TRAF1 through 74 inhibition of NF- $\kappa$ B. A further selection was made based on their inherent kinase selectivity or the 75 uniqueness of the core scaffold for future drug development considerations. To validate the measurement 76 of TRAF1 by flow cytometry, we used RAJI shCTL, shTRAF1 and shPKN1 cell lines (Figure 3A). Control 77 RAJI cells showed a high level of TRAF1 by flow cytometry, shTRAF1 cells showed minimal TRAF1 78 expression and shPKN1 RAJI cells showed an intermediate level of TRAF1, consistent with the Western 79 blot data in Figure 1. Six of the nine compounds tested, PF-941222 (IC<sub>50</sub> for reducing TRAF1= 4.0µM), 80 ipatasertib (IC<sub>50</sub>=  $69\mu$ M), AT7867 (IC<sub>50</sub>=  $1.4\mu$ M), uprosertib (IC<sub>50</sub>=  $4.9\mu$ M), XL-228 (IC<sub>50</sub>=  $2.3\mu$ M) and 81 OTSSP167 ( $IC_{50}$ = 18nM), induced dose-dependent decreases in TRAF1 protein after 24h of treatment of 82 RAJI cells (Figure 3B). Two of the compounds, UNC-2025 and crenolanib increased rather than decreased TRAF1 levels, and tofacitinib, a JAK inhibitor previously shown to inhibit PKN1<sup>34</sup>, had minimal effects on 83 84 TRAF1, potentially due to effects on other kinases. OTSST167, previously known as a MELK inhibitor, 85 was the most potent of the compounds in causing dose-dependent loss of TRAF1. At the highest doses of 86 OTSST167, when TRAF1 levels went below 10% of the original level, we saw induction of cell death in 87 RAJI cells, as evidenced by activated caspase 3 (Figure 3C), albeit about half the cells were resistant to 88 cell death. We next chose OTSST167, as well as a second PKN1 inhibitor that lowered TRAF1, XL-228, 89 for effects on constitutive signaling in RAJI cells (Figure 3D). The loss of TRAF1 in RAJI cells induced 90 by the two inhibitors was associated with dose-dependent loss of pS6 and pNF-κB p65. pERK levels were 91 decreased only at the highest levels of OTSSP167 but not by XL-228. Taken together these data show that 92 inhibitors selected for their ability to inhibit PKN1 and reduce TRAF1 in RAJI cells also reduced 93 constitutive signaling in RAJI, with similar effects as knockdown of PKN1 or TRAF1.

94

95 *PKN1 is constitutively phosphorylated on Thr744 in primary CLL cells* 

9697 To examine PKN1 expression in primary CLL, we obtained frozen PBMC from CLL patients from the

98 Leukemia Tissue Bank of Princess Margaret Hospital /UHN (Table S1). For 8/8 patient CLL samples

99 examined, there was constitutive, relatively uniform expression of PKN1 (Figure S1A and S1B). PKN1

- 100 can be activated by phosphorylation of its activation loop by the kinase PDK1.<sup>35, 36</sup> Of interest, this activated
- 101 pThr774 form of PKN1 was detected in all 8 CLL patient samples examined (Figure S1A and S1B),
- 102 whereas there was lower expression of pThr774 PKN1 in purified B cells from healthy donors (Figure

S1B). Phospho-Thr 774 is also observed in RAJI cells (data not shown). All CLL samples examined also
express TRAF1 protein as well as Zap70, albeit with some variation between samples. These data suggest
that at least a fraction of PKN1 is found in its active, phospho-Thr744 state in CLL cells with minimal
pThr744 PKN1 detected in healthy donor B cells, consistent with a possible role for PKN1 in contributing
to TRAF1 overexpression in CLL.

108

#### 109 *OTSSP167 and XL-228 reduce TRAF1 and increase cell death in most primary CLL samples tested* 110

Elevated expression of TRAF1 in hematopoietic malignancies,<sup>21</sup> combined with evidence in the literature 111 that TRAF1 protects lymphocytes from apoptosis and contributes to lymphomagenesis in mice.<sup>26, 37-39</sup> 112 113 suggests that TRAF1 may contribute to apoptosis-resistance in CLL. However, our attempts to knockdown 114 TRAF1 in primary CLL with the shRNA- lentiviral construct used to knockdown TRAF1 in RAJI cells was 115 unsuccessful, as no viable cells were recovered with lowered TRAF1, potentially due to the importance of 116 TRAF1 in CLL survival. Therefore, we chose 3 PKN1 inhibitors, OTSSP167, XL-228 and AT7867, 117 identified on the basis of their effect on PKN1 in vitro, and their ability to decrease TRAF1 in RAJI cells 118 for their effects on primary CLL patient cells. We monitored intracellular TRAF1 by flow cytometry 24h 119 after treatment and activated caspase-3, as an indicator of apoptotic cell death. CLL cells in the PBMC 120 cultures were identified by co-expression of CD5 and CD19 (Figure 4A). TRAF1 expression was determined by gating on live CD5<sup>+</sup>CD19<sup>+</sup> CLL cells, while frequency of apoptotic cells was determined by 121 122 the gating on cleaved caspase-3<sup>+</sup> cells from CD5<sup>+</sup>CD19<sup>+</sup> single cells without the live gate. OTSSP167 and 123 XL-228 each induced dose-dependent decreases in intracellular TRAF1 protein and increases in activated, 124 cleaved caspase-3 for 16/19 and 9/10 CLL patient samples analyzed, respectively (Figure 4B-C and data 125 not shown). Moreover, the IC<sub>50</sub> for decreasing TRAF1 protein levels was similar to the IC<sub>50</sub> for activating 126 caspase-3 for both OTSSP167 (30.7nM and 33.9nM, respectively) and XL-228 (2.96µM and 2.54µM, 127 respectively) (Figure 4B-C), consistent with the linkage of the two effects. Two outliers (Figure S2) had 128 low TRAF1 to start with and showed a slight increase in TRAF1 with treatment. A third outlier gave 129 equivocal results, with decreases in TRAF1 only at high doses of OTSSP167 (Figure S2). Treatment with 130 the lower affinity inhibitor AT7867 had no effect on TRAF1 expression or cell death in any of the samples 131 (Figure S3A). Analysis of CLL cells at suboptimal concentrations of OTSSP167 (50nM) and XL-228 (4µM), where approximately 20-50% of cells survived treatment, showed a clear dichotomy of cells into a 132 133 TRAF1<sup>lo</sup> and TRAF1<sup>hi</sup> subset. Consistent with a role for TRAF1 in CLL survival, activated caspase-3 was limited to the TRAF1<sup>10</sup> subset of cells within each donor (Figure 4 D-E). Together, these results show that 134 for the majority of primary patient CLL samples tested, treatment with OTSSP167 and XL-228 leads to a 135 136 reduction in TRAF1 protein in CLL cells. The loss of TRAF1 was not secondary to cell death, as TRAF1 137 was measured in the live cell fraction only. Thus, loss of TRAF1 correlates with increased CLL death.

138

139 OTSSP167 and XL-228 decrease the expression of survival molecules in primary CLL cells.
140

141 TNFR family members can upregulate pro-survival Bcl-2 family members via NF-κB signaling.<sup>40</sup> 142 Consistently, 24h after the addition of OTSSP167 and XL-228, Bcl-2 and Mcl-1 protein levels were reduced 143 in CLL cells in a dose-dependent manner (Figure 5A-B). Furthermore, the  $IC_{50s}$  for lowering Bcl-2 and 144 Mcl-1 by OTSSP167 (49.8nM and 25.7nM, respectively) and XL-228 (3.52µM and 2.54µM, respectively) 145 were similar to the IC<sub>50s</sub> for decreasing TRAF1 and increasing caspase-3 activation (Figure 4B-C and 146 Figure 5A-B). We also examined Bcl-X<sub>L</sub>, but the flow cytometry signal in untreated samples was marginal 147 and therefore not analyzed further (data not shown). AT7867, which did not affect TRAF1 and cell death 148 in CLL cells also did not affect Bcl-2 and Mcl-1 expression (Figure S3B). These results show that the 149 kinase inhibitors OTSSP167 and XL-228 reduce the level of TRAF1 protein in primary CLL cells and this 150 decrease is associated with concomitant reductions of Bcl-2 and Mcl-1. 151

- 152 OTSSP167 and XL-228 decrease signaling intermediates in primary CLL cells.
- 153

154 TRAF1 enhances NF-κB, MAPK and pS6 activation downstream of TNFRs such as CD40, CD30, TNFR2, 4-1BB and the EBV encoded TNFR LMP1.<sup>16, 39, 41-46</sup> Therefore, we asked how reduction of TRAF1 155 156 impacted these downstream signaling pathways in live, primary CLL cells. After treatment of CLL cells 157 with OTSSP167 for 24h, we observed a dose-dependent decrease in pNF- $\kappa$ B p65 (IC<sub>50</sub> = 0.32 $\mu$ M), pS6 158  $(IC_{50} = 0.31 \mu M)$  and pERK  $(IC_{50} = 1.04 \mu M)$  (Figure 6A). Likewise, treatment of CLL cells with XL-228 159 resulted in a dose-dependent decrease in pNF- $\kappa$ B (IC<sub>50</sub> = 2.47 $\mu$ M), pS6 (IC<sub>50</sub> = 1.44 $\mu$ M) and pERK (IC<sub>50</sub> = 160 2.23 $\mu$ M) (Figure 6B). In contrast, treatment of cells with AT7867 did not affect levels of pNF- $\kappa$ B, but 161 slightly reduced pS6 and pERK (Figure S3C). As AT7867 had no effect on decreasing TRAF1 in primary 162 CLL cells, the lack of effect on pNF-κB p65 is expected. As summarized in Table S4, AT7867 also inhibits AKT1.2 and 3 as well as S6K, possibly explaining the effects on pS6. These results show that the decreases 163 164 in TRAF1 observed in primary CLL cells after treatment with PKN1 inhibitors are associated with a 165 reduction in levels of pNF- $\kappa$ B p65, pS6 and pERK and largely recapitulate the results seen in RAJI cells.

166

PKN1 inhibition in combination with venetoclax results in increased CLL death correlating with reduced
levels of TRAF1 and Bcl-2 family proteins

Venetoclax, a BH3 mimetic that antagonizes Bcl-2 and induces apoptosis is approved for the treatment of 170 patients with relapsed and 17p deleted CLL.<sup>7, 47</sup> Although showing great promise, mechanisms of 171 venetoclax resistance are emerging.48,49 The finding that inhibitors that targeted TRAF1 also reduced Bcl-172 173 2 and Mcl-1 levels in CLL cells suggested these inhibitors might be complementary to venetoclax. 174 Therefore, we examined effects of the stronger of the two inhibitors, OTSSP167, in combination with 175 venetoclax. Fewer than 15% of primary CLL cells died when treated with suboptimal OTSSP167 (10nM) 176 or venetoclax (1nM) alone (Figure 7A). However, when cells were treated with increasing concentrations 177 of venetoclax in combination with suboptimal (10nM) OTSSP167, the IC<sub>50</sub> for cell death (1.71nM) was 178 decreased 5.8-fold compared to venetoclax treatment alone (9.91nM) (Figure 7B). However, when cells 179 were treated with increasing amounts of OTSSP167 in combination with suboptimal (1nM) venetoclax, the 180 IC<sub>50</sub> for cell death was only reduced 1.9-fold to 23.7nM from 45.9nM with OTSSP167 treatment alone 181 (Figure 7C). At the dose of venetoclax that resulted in approximately 50% death, we also observed that CLL cells from 4 of 6 patients were enriched for TRAF1<sup>hi</sup> cells after venetoclax treatment. The addition of 182 suboptimal OTSSP167 in combination with this dose of venetoclax eliminated this TRAF1<sup>hi</sup> subset (Figure 183 184 7D). Further analyses of the TRAF1<sup>hi</sup> and TRAF1<sup>lo</sup> subsets showed that TRAF1<sup>hi</sup> cells have higher expression of Bcl-2 family members Mcl-1 and Bcl-2 than TRAF1<sup>lo</sup> cells (Figure 7E). Given the lack of 185 186 effect of venetoclax in lowering TRAF1, this may explain the reduced effects on cell death when suboptimal 187 venetoclax is added to OTSSP167 as OTSSP167 alone effectively eliminates both TRAF1<sup>lo</sup> and TRAF1<sup>hi</sup> populations (Figure 7 C, F). Taken together, these data show that by targeting TRAF1, the inhibitor 188 OTSSP167 has complementary effects with venetoclax on CLL cells by eliminating TRAF1<sup>hi</sup>, Bcl-2 and 189 190 Mcl-1 co-expressing venetoclax-resistant cells (Figure 7G). Moreover, measurement of TRAF1 provides 191 a useful marker of the effectiveness of OTSSP167 in inducing death CLL cells.

# 193 Discussion

194

192

PKN1, a ubiquitous kinase, has been implicated as an effector of Rho GTPases <sup>50, 51</sup> and in regulation of 195 cell migration.<sup>52-55</sup> Here, we reveal another role for PKN1 in maintaining the stability of TRAF1 protein in 196 197 lymphoma and CLL cells. Knockdown and restoration experiments in RAJI and 293 cells confirmed the need for PKN1 phosphorylation of TRAF1 S146 to prevent TRAF1 degradation during constitutive CD40 198 199 signaling in RAJI cells. During TNFR family signaling, TRAF1 is important in the recruitment of cIAPs for downstream NF- $\kappa$ B and MAPK signaling.<sup>39</sup> As cIAPs can add K48-linked polyubiquitin to trigger 200 201 protein degradation as well as K63-linked polyubiquitin to scaffold downstream signaling, we hypothesized 202 that phosphorylation of TRAF1 by PKN1 is required to protect it from cIAP-induced degradation during 203 constitutive TNFR family signaling in B cell related cancer cells. The finding that SMAC mimetics that 204 induce degradation of cIAPs abrogated TRAF1 degradation in the CD40 signalosome with little impact on

205 the cytosolic TRAF1 pool supports this hypothesis. PKN1 is regulated by phosphorylation on its activation 206 loop by PDK1.<sup>35, 36</sup> This active pThr774 form of PKN1 was readily detected by western blot in CLL patient 207 samples, whereas substantially lower levels were detected in normal B cells from healthy donors. As PDK1 208 can be activated downstream of BCR signaling, the activation of PKN1 may be explained by constitutive 209 BCR signaling in CLL cells.<sup>56</sup> Thus, the presence of TRAF1 and the pThr744 form of PKN1 might be a useful adjunct in CLL screening. Interestingly, PDK1 and active PKN1 have also been noted in other 210 211 cancers, with particularly high expression in ovarian serous carcinoma, suggesting that inhibition of PKN1 212 might have broader use.<sup>57</sup>

213

214 TRAF1 is an NF- $\kappa$ B induced protein that enhances NF- $\kappa$ B signaling downstream of TNFRs. Here we 215 showed that decreasing TRAF1 by inhibition of PKN1 has the potential to break this feed-forward NF-κB 216 signaling loop in TNFRSF-dependent cancers. Our study identified two compounds, OTSSP167 and XL-217 228, that when added to primary patient CLL cells induced dose dependent loss of TRAF1, pS6, pNF- $\kappa$ B 218 p65, pERK. Mcl-1 and Bcl-2, and concomitant induction of cell death. This was not secondary to cell death, 219 because we gated on live cells for all measurements except activated caspase 3 which was measured on the 220 total population of CLL cells. Moreover, in RAJI cells, cell death was observed only when TRAF1 levels 221 were reduced to minimal levels and RAJI death plateaued at 50%. This suggests RAJI may have 222 compensatory mechanisms for survival compared to CLL, which show 100% loss of viability at high doses 223 of the inhibitors. The correlation between decreased TRAF1 protein levels, decreased downstream signals 224 and increased caspase-3 activation at similar IC<sub>50</sub>, is consistent with a direct effect through the pPKN1-225 pTRAF1-NF- $\kappa$ B/MAPK/pS6 signaling axis. In contrast, another inhibitor AT7867, with a higher IC<sub>50</sub> for 226 inhibiting PKN1 failed to decrease TRAF1 significantly in CLL cells and showed no effect on the 227 downstream signals or cell death. OTSSP167 is also known as a MELK inhibitor. OTSSP167 has been 228 tested in phase 1/2 trials for breast cancer and acute myeloid leukemia, and has been suggested as a CLL treatment based on its ability to induce apoptosis in primary CLL cells.<sup>58</sup> However, many inhibitors, and in 229 particular OTSSP167, have broad effects on multiple kinases.<sup>59</sup> Thus, it is possible that the effects of 230 OTSSP167 on PKN1 contributed to CLL cell death in MELK inhibitor studies.<sup>58</sup> The finding that 231 232 OTSSP167 and XL-228 show an order of potency for inhibiting TRAF1 and its downstream signals that 233 matches the order of potency for PKN1 inhibition is also consistent with these drugs acting on PKN1. 234 OTSSP167, with 11 nM IC<sub>50</sub> for PKN1 inhibition in vitro and an IC<sub>50</sub> for decreasing TRAF1 and increasing 235 apoptosis of CLL cells of 30 nM, represents a good starting point for future drug discovery efforts to identify 236 a more potent and selective PKN1 inhibitor. Other drugs identified as potential PKN1 inhibitors in vitro, such as the JAK inhibitor tofacitinib,<sup>34</sup> were not effective in lowering TRAF1 (Figure 3B), potentially 237 because their effects on other targets counteracted the potential effect on PKN1, although this was not 238 239 further investigated here.

240

241 There was no correlation between TRAF1 levels pre-treatment or of sensitivity to PKN1 inhibition based 242 on Rai stage of the CLL patients. Of 19 CLL patient samples examined for effects of OTSSP167, 16 showed 243 a strong correlation between loss of TRAF1 and gain of caspase 3. Of the 3 outliers, two had very low 244 TRAF1 levels to start with. One CLL patient sample showed an initial small increase in TRAF1 followed 245 by loss of TRAF1 at the concentrations where most cells showed activated caspase 3. Although, IgM mutant 246 status of the donors was not available for these banked CLL samples, the finding that the majority of 247 samples tested responded to a treatment that lowers TRAF1, and that most CLL cells have high TRAF1 248 levels, suggests the utility of this approach across CLL patient groups. Of note an enrichment for TRAF1<sup>hi</sup> 249 cells was also observed at suboptimal venetoclax doses for 4/6 donors tested. This might reflect selective loss of TRAF1<sup>10</sup> cells, leading to enrichment of the TRAF1<sup>hi</sup> cells at low inhibitor doses, consistent with an 250 251 important role for TRAF1 in CLL cell survival and potentially venetoclax resistance. Thus, addition of a 252 TRAF1 inhibitor, via PKN1 inhibition, has the potential to target venetoclax resistance. 253

254 While there has been much recent interest and success in targeting antigen receptor signaling and Bcl-2 in B cell malignancies<sup>5</sup>, to date there has been minimal attention paid to TNFR-mediated survival signaling. 255 TRAF-binding TNFR family members in the tumor microenviroment can contribute key survival signals 256 to CLL cells,<sup>2, 60, 61</sup> and there is accumulating evidence for the importance of CD40L in promoting drug 257 resistance and contributing to tumor cell survival in the lymphoid microenvironment.<sup>62, 63</sup> The value of the 258 259 PKN1-TRAF1 signaling axis as a target for CLL lies in its role downstream of many TNFRSF members and the fact that TNFRSF signaling contributes to NF-KB, MAPK signaling, as well as induction of pS6, 260 an important determinant of cell size and cancer cell fate.<sup>64, 65</sup> Thus, targeting this pathway could be 261 262 complementary to drugs that target Bcl-2 family members and/or BCR signaling. In particular, we showed that OTSSP167 synergizes with venetoclax in inducing cell death. Although Mcl-1 inhibitors are being 263 developed to target venetoclax resistance,<sup>66</sup> these inhibitors do not target all Bcl-2 family members. 264 TNFRSF signaling has also been implicated in inducing other pro-survival Bcl-2 family members, such as 265 266 Bcl-x<sub>L</sub> and Bfl-1.<sup>67</sup> In contrast to Bcl-2 family members, which are important in multiple cell types, TRAF1 267 expression is limited to activated cells of the immune system. Thus, inhibition of PKN1-TRAF1-dependent TNFRSF signaling to inhibit NF-κB, MAPKs and pS6 might offer improved long-term protection against 268 269 relapse.

270 271

## 272 Author contributions

M.I.E., J.C.L. A.A.A.-S. and T.H.W. designed experiments, analyzed data, and wrote the manuscript. J.
C.L., M.I.E. and A.A.A.-S, with help from K.T., S.Z. and A.M., performed experiments. A.A. helped with
CLL sample coordination and clinical data. D.U., M.I., MP. and R.A. provided medicinal chemistry
expertise and contributed the OICR inhibitor library. M.M. provided samples, clinical data and insight.

- 277278 Acknowledgements
- 279

We thank Ann McPherson for generating TRAF1- knockdown RAJI cells, Juan Carlos Zúñiga-Pflücker for
 providing OP9 stromal cells, Dionne White, Joanna Warzyszynska, Nathalie Simard and Janine Charron
 for assistance with flow cytometry, Birinder Ghumman for technical assistance, and all the patients for
 participating and donating samples to make this study possible. This research was funded by a Foundation
 grant from the Canadian Institute of Health Research (FDN-143250) and an Innovation grant from the
 Canadian Cancer Society Research Institute (2012-701326) to T.H.W.

- 287 Competing financial interests
- 288
- 289 MIE, AAS and THW have filed intellectual property on PKN1 inhibition.
- 290
- 291
- 292

293			
294	References		
295			
296 297 298 299	1.	Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, <i>et al.</i> Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. <i>Nature</i> 2012 Sep 13; <b>489</b> (7415): 309-312.	
300 301 302 303	2.	Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, <i>et al.</i> The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. <i>Blood</i> 2011 Jan 13; <b>117</b> (2): 563-574.	
304 305	3.	Routledge DJ, Bloor AJ. Recent advances in therapy of chronic lymphocytic leukaemia.	
306 307		<i>Br J Haematol</i> 2016 Aug; <b>174</b> (3): 351-367.	
308 309 310 311	4.	Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, <i>et al.</i> Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> 2018 Apr 12; <b>131</b> (15): 1704-1711.	
312 313 314	5.	Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. <i>Blood</i> 2015 Jul 23; <b>126</b> (4): 471-477.	
315 316 317 318	6.	Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, <i>et al.</i> Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>N Engl J Med</i> 2015 Dec 17; <b>373</b> (25): 2425-2437.	
319 320 321 322	7.	Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, <i>et al.</i> Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J</i> <i>Med</i> 2016 Jan 28; <b>374</b> (4): 311-322.	
323 324 325	8.	Frey NV, Porter DL. CAR T-cells merge into the fast lane of cancer care. <i>Am J Hematol</i> 2016 Jan; <b>91</b> (1): 146-150.	
326 327 328	9.	Jain N, O'Brien S. Targeted therapies for CLL: Practical issues with the changing treatment paradigm. <i>Blood Rev</i> 2016 May; <b>30</b> (3): 233-244.	
329 330 331	10.	Jain N, O'Brien S. BCR inhibitor failure in CLL: an unmet need. <i>Blood</i> 2016 Nov 3; <b>128</b> (18): 2193-2194.	
332 333 334 335	11.	Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. <i>Br J Haematol</i> 1999 Sep; <b>106</b> (4): 995-1004.	
336 337 338	12.	Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, Gordon J, <i>et al.</i> Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. <i>Oncogene</i> 2005 Nov 24; <b>24</b> (53): 7913-7923.	

339		
340	13.	Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, et al. Ligand-
341		independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-
342		Reed-Sternberg cells. Oncogene 2002 Apr 11; 21(16): 2493-2503.
343		
344	14.	Eliopoulos AG, Waites ER, Blake SM, Davies C, Murray P, Young LS. TRAF1 is a
345		critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr
346		virus-encoded latent infection membrane protein 1 but not CD40. J Virol 2003 Jan:
347		77(2): 1316-1328.
348		
349	15.	Xie P. TRAF molecules in cell signaling and in human diseases. <i>J Mol Signal</i> 2013: <b>8</b> (1):
350	101	7
351		
352	16	Wang CY Mayo MW Korneluk RG Goeddel DV Baldwin AS Jr NF-kannaB
252	10.	antianontosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress
357		caspase-8 activation Science 1008: <b>281</b> : 1680-1683
255		caspase-6 activation. Science 1996, 201. 1060-1065.
356	17	Zheng C. Kabaleeswaran V. Wang V. Cheng G. Wu H. Crystal structures of the TRAF2:
257	1/.	LIAD2 and the TPAE1: TPAE2: cIAD2 complexes: affinity specificity and regulation
220		$M_{ol} C_{oll} 2010 \text{ Apr} 0.39(1), 101, 112$
220		<i>Mol Ceu</i> 2010 Api 9, <b>30</b> (1): 101-115.
202	10	Elevate D. Denson MI. de Vries VC. Wesight A. Cue V. Neelle DI. Melecular
300	18.	Eigueta K, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noene KJ. Molecular
301		mechanism and function of CD40/CD40L engagement in the immune system. <i>Immunoi</i>
362		Rev 2009 May; 229(1): 152-172.
303	10	Destruction MI Miletin and C Distance KM He WC Dave In certain Later LADI
364	19.	Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1
365		and CIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1
366		ubiquitination. <i>Mol Cell</i> 2008 Jun 20; <b>30</b> (6): 689-700.
367	20	
368	20.	Li X, Yang Y, Ashwell JD. INF-KII and c-IAPI mediate ubiquitination and degradation
369		of 1RAF2. <i>Nature</i> 2002 Mar 21; <b>416</b> (68/8): 345-347.
370	0.1	
371	21.	Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K, Monks A, et al. TNFR-
372		associated factor family protein expression in normal tissues and lymphoid malignancies.
373		<i>J Immunol</i> 2000 Nov 1; <b>165</b> (9): 5084-5096.
374		
375	22.	Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, et al. Genetic
376		variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.
377		<i>Blood</i> 2007 Dec 15; <b>110</b> (13): 4455-4463.
378		
379	23.	Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, et al. Early lethality,
380		functional NF-kB activation, and increased sensitivity to TNF-induced cell death in
381		TRAF2-deficient mice. Immunity 1997; 7: 715-725.
382		
383	24.	Zapata JM, Reed JC. TRAF1: lord without a RING. Sci STKE 2002 May 21; 2002(133):
384		PE27.

385		
386	25.	Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, et al. TRAF1 is
387		a negative regulator of TNF signaling: Enhanced TNF signaling in TRAF1-deficient
388		mice. <i>Immunity</i> 2001; <b>15</b> (4): 647-657.
389		
390	26.	Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF. NF-kappaB2 mutation targets TRAF1
391		to induce lymphomagenesis. <i>Blood</i> 2007 Jul 15; <b>110</b> (2): 743-751.
392		
393	27.	Kato T, Jr., Gotoh Y, Hoffmann A, Ono Y. Negative regulation of constitutive NF-
394		kappaB and JNK signaling by PKN1-mediated phosphorylation of TRAF1. Genes Cells
395		2008 May; <b>13</b> (5): 509-520.
396		
397	28.	Grinshtein N. Datti A. Fujitani M. Uehling D. Prakesch M. Isaac M. et al. Small
398		molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for
399		neuroblastoma tumor-initiating cells. <i>Cancer Res</i> 2011 Feb 15: <b>71</b> (4): 1385-1395.
400		
401	29.	Trzcinska-Daneluti AM, Nguyen L, Jiang C, Fladd C, Uehling D, Prakesch M, et al. Use
402	_,.	of kinase inhibitors to correct DeltaF508-CFTR function. <i>Mol Cell Proteomics</i> 2012 Sep:
403		11(9): 745-757.
404		
405	30.	Choi H-S. Wang Z. Richmond W. He X. Yang K. Jlang T. et al. Design and synthesis of
406	20.	7H-pyrrolo[2 3-d]pyrimidines as focal adhesion kinase inhibitors Part 1 <i>Bioorganic and</i>
407		Medicinal Chemistry Letters 2006: 16(8): 2173-2176
407		inearchiai Chemisiry Letter's 2000; <b>10</b> (0): 2175 2170.
409	31.	Rothe M. Sarma V. Dixit VM. Goeddel DV. TRAF2-mediated activation of NF-kappa B
410	51.	by TNF recentor 2 and CD40. Science 1995: 269: 1424-1427
410 411		by 11(1 1000ptol 2 and 01) 10. Selence 1999, <b>209</b> , 1121 1127.
412 412	32	Metzger F. Vin N. Wissmann M. Kunowska N. Fischer K. Friedrichs N. <i>et al</i>
412	52.	Phosphorylation of historie H3 at threonine 11 establishes a novel chromatin mark for
413 414		transcriptional regulation Nat Cell Riol 2008 Jan: 10(1): 53-60
414 //15		transcriptional regulation. <i>Nul Cell Diol</i> 2000 Jan, <b>10</b> (1): 55-00.
415 //16	33	Darding M Feltham R Teney T Bianchi K Benetatos C Silke I <i>et al</i> Molecular
410 //17	55.	determinants of Smac mimetic induced degradation of cIAP1 and cIAP2 <i>Cell Death</i>
417 //18		Differ 2011 Aug: $18(8)$ : 1376-1386
410 //10		<i>Dijjer</i> 2011 Mug, <b>10</b> (0): 1570 1500.
419	3/	Ostrovskyi D. Rumpf T. Fib I. Lumbroso A. Slynko I. Klaeger S. at al. Tofacitinib and
420	Јт.	analogs as inhibitors of the histore kinase PRK1 (PKN1) Euture Med Chem 2016 Sen:
421		$\mathbf{g}(12) \cdot 1527 \ 1551$
422		<b>0</b> (15), 1557-1551.
425	25	Dong IO Landa IP Wick MI Thu I Mukai H One V at al Phoenhomelation of
424	55.	protein kinase N by phosphoinositide dependent protein kinase 1 mediates insulin signals
425		to the patin extended to a Reac Natl Acad Sci U.S. A 2000 May 0: 07(10): 5080-5004
420		to the actin cytoskereton. I for wait Actual Sci $0.5 A 2000$ (May 9, 97(10); $5089-5094$ .
427 120	36	Flynn P. Mellor H. Casamassima A. Parker DI. Phy GTPasa control of protain kings C.
420 120	50.	related protein kinase activation by 2 phosphoinositide dependent protein kinase <i>I Dial</i>
429		Cham 2000 Apr 14: 275(15): 11064 11070
450		Chem 2000 Apr 14, 273(13), 11004-11070.

431		
432	37.	Speiser DE, Lee SY, Wong B, Arron J, Santana A, Kong YY, et al. A regulatory role for
433		TRAF1 in antigen-induced apoptosis of T cells. J Exp Med 1997; 185(10): 1777-1783.
434		
435	38.	Sabbagh L, Pulle G, Liu Y, Tsitsikov EN, Watts TH. ERK-Dependent Bim Modulation
436		Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell
437		Survival In Vivo. J Immunol 2008 Jun 15; 180(12): 8093-8101.
438		
439	39.	Edilova MI, Abdul-Sater AA, Watts TH, TRAF1 Signaling in Human Health and
440		Disease. Front Immunol 2018: 9: 2969.
441		
442	40.	Croft M. The role of TNF superfamily members in T-cell function and diseases. <i>Nat Rev</i>
443	101	Immunol 2009 Apr. 9(4): 271-285
444		Initiation 2009 (1): 2/1 200.
445	41	Arron IR Pewzner-Jung Y Walsh MC Kobayashi T Choi Y Regulation of the
446		subcellular localization of tumor necrosis factor recentor-associated factor (TRAF)? by
447		TRAF1 reveals mechanisms of TRAF2 signaling <i>LExp Med</i> 2002 Oct 7: <b>196</b> (7): 923-
448		934
449		
450	42	Greenfeld H. Takasaki K. Walsh MJ. Ersing J. Bernhardt K. Ma Y. <i>et al.</i> TRAF1
451	. 2.	Coordinates Polyubiquitin Signaling to Enhance Enstein-Barr Virus LMP1-Mediated
452		Growth and Survival Pathway Activation PLoS Pathog 2015 May: 11(5): e1004890
452		Showin and Survival Fallway Henvalon. $F Dob F amog 2015 May, \mathbf{H}(5). Crookers.$
454	43.	Guo F. Sun A. Wang W. He J. Hou J. Zhou P. <i>et al.</i> TRAF1 is involved in the classical
455		NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma
456		cells <i>Mol Immunol</i> 2009 Jun 18
457		
458	44.	McPherson AI Snell I.M. Mak TW. Watts TH. Opposing roles for TRAF1 in the
459		alternative versus classical NF-kappaB pathway in T cells. <i>The Journal of hiological</i>
460		<i>chemistry</i> 2012 June 29, 2012; <b>287</b> (27); 23010-23019
461		enemistry 2012 build 29, 2012, 201(27), 25010 25019.
462	45	Xie P. Hostager BS. Munroe ME. Moore CR. Bishon GA. Cooperation between TNF
463	10.	recentor-associated factors 1 and 2 in CD40 signaling <i>Limmunol</i> 2006 May 1: <b>176</b> (9).
463		5388-5400
465		
405	46	Wong C Edilova MI Wager I E Muijb S Singer M Dermard NE at al Effect of II 7
400	<b>-</b> 0.	Therapy on Phoenho Ribosomal Protein S6 and TRAF1 Expression in HIV Specific CD8
407		T Cells in Patients Receiving Antiretroviral Therapy, <i>Limmunol</i> 2018 Jan 15: 200(2).
400		558 564
409		558-504.
470	17	Stilsenhouse & Fishhaust D. Schotalia I. Contra & Source I. Marin T. (1
471	4/.	Venetoelev in released or refrectory chronic lymphosytic leukaemic with 17n deletion a
472		will icentra open lobal phase 2 study Langet Oneol 2016 June 17(6): 768 778
473		municenite, open-raber, phase 2 study. Lancer Oncor 2010 Jun, 17(0): 700-778.
+/4 175	48	Bose P. Gandhi V. Kononleva M. Pathways and mechanisms of venetoclay resistance
476	то.	Leuk Lymphoma 2017 Sep; 58(9): 1-17.

477		
478	49.	Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential
479		mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer
480		2017 Jun 2; <b>17</b> (1): 399.
481		
482	50.	Amano M, Mukai H, Ono Y, Chihara K, Matsui T, Hamaiima Y. et al. Identification of a
483		putative target for Rho as the serine-threonine kinase protein kinase N. Science 1996 Feb
484		2: <b>271</b> (5249): 648-650.
485		
486	51.	Watanabe G. Saito Y. Madaule P. Ishizaki T. Fujisawa K. Morij N. <i>et al.</i> Protein kinase
487	011	N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho. <i>Science</i>
488		1996 Feb 2: 271(5249): 645-648
400		
400	52	Iilg CA Ketscher A Metzger E Hummel B Willmann D Russeler V <i>et al</i>
491	02.	PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer
491 //Q2		cells Oncotarget 2014 Dec 30: 5(24): 12646-12664
102		(213. 0)
493 494	53	Mashud R. Nomachi A. Havakawa A. Kubouchi K. Danno S. Hirata T. et al. Impaired
494 495	55.	lymphocyte trafficking in mice deficient in the kinase activity of PKN1. Sci Rep 2017
106		Suppose the function of the function of the function of the function of the function $\Lambda_{110}$ of $7(1)$ · 7663
490		Aug 7, 7(1). 7005.
497	54	Vuan O. Ren C. Xu W. Petri B. Zhang I. Zhang V. at al. PKN1 Directs Polarized RAB21
498	Э <b>т</b> .	Vasiela Trafficking via PDH3A and Is Important for Neutronhil Adhesion and Ischemia
499 500		Reperfusion Injury Call Ran 2017 Jun 20: 10(12): 2586-2507
500		Repetitusion injury. Cett Rep 2017 Juli 20, $17(12)$ . 2500-2577.
502	55	Zeng R. Wang Z. Li X. Chen V. Vang S. Dong I. Cyclin-dependent kinase 1-mediated
502	55.	phosphorylation of protein kinase N1 promotes anchorage independent growth and
504		migration Cell Signal 2020 Jan 22: 60: 1005/6
505		ingration. Cett Signut 2020 Juli 22, 07: 107540.
506	56	Baracho GV Cato MH Zhu Z Jaren OR Hoheika E Reth M at al PDK1 regulates B
507	50.	cell differentiation and homeostasis Proc Natl Acad Sci U.S. A 2014 Jul 1: 111(26).
502		0573 0578
508		<i>7575-757</i> 8.
509	57	Calgana MT Congway M Spanaer AM Deschol DM Frierson HE Ir DDV1 distribution
510	57.	in normal tissues and carainomas: overexpression and activation in overion serous
511		aproince Human nathology 2000 Oct. <b>40</b> (10): 1424-1440
512		carcinoma. <i>Trumun puthology</i> 2009 Oct, $40(10)$ : 1454-1440.
513	50	Thong V. Thou V. Li V. Vu V. Li D. et al. Inhibition of maternal embryonic
514	50.	Lauging T, Zhou X, Li T, Xu T, Lu K, Li F, <i>et al.</i> Infibition of finatematemotyofic
515		lumphoavitio louleario (neogene 2018 Oct. 27(41): 5520 5522
510 E17		1y mphocytic reakenna. Oncogene 2016 Oct, $3/(41)$ ; $3320$ -3335.
51/ E10	50	Klasson & Heinzlmein & Wilhelm M. Delzer H. Vielt D. Keenie DA et al. The terrest
510 E10	39.	Landsonn of clinical tringer drugs. Science 2017 Dec 1: 259(62(7))
213		ranuscape of chinical kinase drugs. Science 2017 Dec 1; <b>338</b> (6367).
520		

521 522 523 524	60.	Cols M, Barra CM, He B, Puga I, Xu W, Chiu A, <i>et al.</i> Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. <i>J Immunol</i> 2012 Jun 15; <b>188</b> (12): 6071-6083.
525 526 527 528	61.	Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, <i>et al.</i> Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. <i>Blood Adv</i> 2017 Jun 13; <b>1</b> (14): 933-946.
529 530 531 532	62.	Oppermann S, Ylanko J, Shi Y, Hariharan S, Oakes CC, Brauer PM, <i>et al.</i> High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. <i>Blood</i> 2016 Aug 18; <b>128</b> (7): 934-947.
533 534 535	63.	Crassini K, Shen Y, Mulligan S, Giles Best O. Modeling the chronic lymphocytic leukemia microenvironment in vitro. <i>Leuk Lymphoma</i> 2017 Feb; <b>58</b> (2): 266-279.
536 537 538	64.	Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. <i>Trends Biochem Sci</i> 2006 Jun; <b>31</b> (6): 342-348.
539 540 541	65.	Sulima SO, Hofman IJF, De Keersmaecker K, Dinman JD. How Ribosomes Translate Cancer. <i>Cancer Discov</i> 2017 Oct; <b>7</b> (10): 1069-1087.
542 543 544 545	66.	Besbes S, Pocard M, Mirshahi M, Billard C. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia. <i>Crit Rev Oncol Hematol</i> 2016 Apr; <b>100:</b> 32-36.
546 547 548 549 550	67.	Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4-1BB Promotes the Survival of CD8(+) T Lymphocytes by Increasing Expression of Bcl-x(L) and Bfl-1. <i>J Immunol</i> 2002; <b>169</b> (9): 4882-4888.

### 551 Figure Legends

552

553 Figure 1. PKN1 kinase activity and TRAF1 S146 are required for TRAF1 protein stability. (A) RAJI 554 or Daudi cells were stably transduced with lentiviruses expressing control shRNA (shCTL), with shRNA 555 targeting TRAF1 (shTRAF1) or with shRNA targeting PKN1 (shPKN1) and whole cell lysates were 556 subjected to western blot analysis for TRAF1, PKN1 or GAPDH. (B) shCTL or shPKN1 RAJI cells were 557 treated with cycloheximide for the indicated times in hours (h), then whole cell lysates were subjected to 558 western blot to determine TRAF1, PKN1 or GAPDH levels as indicated on the figures (C,D). 293T cells 559 stably transduced with shCTL (C) or shPKN1 (D) lentiviruses were transiently transfected with WT TRAF1 560 or with TRAF1 S146A expression plasmids. Cells were treated or not with cycloheximide (CHX) for the 561 indicated times, then whole cell lysates were subjected to Western blot analysis of TRAF1, PKN1 or 562 GAPDH levels. (E) shPKN1 293T cells were transiently co-transfected with TRAF1 as well as shPKN1-563 resistant WT or K644E (kinase dead) PKN1. Cells were then treated with cycloheximide (CHX) and then 564 cell lysates were subjected to Western blot to analyze TRAF1, PKN1 or GAPDH levels. All experiments 565 were repeated at least two times. Densitometry results are indicated to the right of each gel.

566

Figure 2. PKN1 is required to protect TRAF1 from cIAP-mediated degradation during CD40 signaling in RAJI cells, thereby contributing to TRAF1 dependent signaling. (A) shCTL or shPKN1 RAJI cells were treated with cycloheximide (CHX) for the indicated times, with or without SMAC mimetic BV6 treatment, then the CD40 signaling complex was immunoprecipitated from whole cell lysates (IP1).

571 TRAF1 was then immunoprecipitated from the supernatants of the CD40 immunoprecipitates (IP2). IP1, 572 IP2 or whole cell lysates were analyzed for levels of TRAF1 by Western blotting. (B) shCTL, shTRAF1 or 573 shPKN1 RAJI cells were serum starved for 24h to reduce constitutive signaling then serum was added back 574 for the indicated times and whole cell lysates were analyzed by Western blotting for levels of p-ERK1/2, 575 p-S6 or  $\beta$ -actin as indicated in the figure. Each panel has been repeated at least 3 times. Densitometry results 576 indicated below the figure and are reported as the average of two similar experiments.

576

578 Figure 3. Identification of PKN1 inhibitors that decrease TRAF1 protein levels and constitutive 579 signaling in RAJI cell lines. (A) Base line expression of TRAF1 in shCTL, shTRAF1 and shPKN1 RAJI 580 cell lines, representative of 7 independent experiments. (B) shCTL RAJI cells were treated with the 581 indicated inhibitor at doses ranging from 0.1nM-10µM for 24h. TRAF1 expression was measured by 582 intracellular flow cytometry after treatment. dMFI refers to the MFI for the TRAF1 stain minus the FMO 583 (background) control. To calculate the  $IC_{50}$  for PF-941222, AT7867, ipatasertib and uprosertib where 584 TRAF1 expression was not maximally reduced, TRAF1 was assumed to reach 0 dMFI. N.D. = not determined. (C). Effect of OTSST167 on TRAF1 levels and death of RAJI cells measured by activated 585 586 caspase 3. (D) Baseline expression of TRAF1 and phosphorylation of signaling intermediates pS6, pNF-587 κBp65 and pERK in shCTL, shPKN1 and shTRAF1 RAJI cell lines (top). shCTL RAJI cells were treated 588 with OTSSP167 or XL-228 at the indicated concentration for 24h. TRAF1, pS6, pNF-κBp65 and pERK 589 were measured by flow cytometry (middle, bottom). Data are representative of 2 independent experiments.

590

591 Figure 4. OTSSP167 and XL-228 decrease TRAF1 protein levels and increase cell death in primary

592 CLL cells. (A) Representative gating strategy to identify CLL cells. TRAF1 and cleaved caspase-3

593 expression were measured in CLL cells by flow cytometry after treatment with DMSO control or (B)

594 OTSSP167 or (C) XL-228 for 24h at the indicated concentrations. In panels (B) and (C), line graphs (top)

show TRAF1 dMFI and %cleaved caspase- $3^+$  cells as mean  $\pm$  SD. Histograms from one representative donor depict TRAF1 MFI (bottom left) and cleaved caspase-3 MFI (bottom right) in CLL cells after

596 donor depict 1 RAF1 MF1 (bottom left) and cleaved caspase-3 MF1 (bottom right) in CLL cells after 597 treatment with DMSO or inhibitors. TRAF1 MFI was determined by gating on Live CD5+CD19+

598 CLL cell. Frequency of cleaved caspase-3+ cells was determined by gating on CD5+CD19+

599 single cells. (D, E)

600 (B, D) n=6 CLL patient samples, 2 experiments pooled. Representative of a total of 16 donors across 8
601 total experiments. (C, E) n=6 CLL patient samples, 2 experiments pooled. Representative of a total of 9
602 donors across 4 total experiments.

603

**Figure 5. OTSSP167 and XL-228 decrease the level of Bcl-2 and Mcl-1 protein expression in primary CLL cells.** Bcl-2 and Mcl-1 expression were measured in live CLL cells after treatment with DMSO control or (A) OTSSP167 or (B) XL-228 for 24h at the indicated concentrations. In each panel, line graphs (left) show mean dMFI  $\pm$  SD, n=6 CLL patient samples (2 independent experiments pooled), and histograms (right) from a representative donor depict the MFI of Bcl-2 or Mcl-1 in CLL cells after treatment with DMSO or the indicated concentration of inhibitor. The same 6 CLL samples are shown here as in figure 4.

610

611 Figure 6. OTSSP167 and XL-228 decrease the level of signaling intermediates in primary CLL cells. 612 Phosphorylated signaling intermediates pS6, pNF-κBp65 and pERK were measured in live CLL cells after 613 treatment with DMSO control or (A) OTSSP167 or (B) XL-228 for 24h at the indicated concentrations. In 614 each panel, line graphs (left) show mean dMFI  $\pm$  SD, n=6 CLL patient samples (2 independent experiments 615 pooled), and histograms (right) from a representative donor depict the MFI of pS6, pNF-κBp65 or pERK 616 in CLL cells after treatment with DMSO or the indicated concentration of inhibitor. The same 6 CLL

- 617 samples were used here as in figures 4 and 5.
- 618

619 Figure 7. Increased cell death following combined treatment with OTSSP167 and venetoclax. Primary 620 CLL cells were cultured on OP9 stromal cells and cleaved caspase-3 expression was measured by flow 621 cytometry following 24h of treatment with: (A) DMSO, 10 nM OTSSP167 or 1 nM venetoclax, (B) 0.1 622 nM-100 nM VEN  $\pm$  10 nM OTSSP167 or (C) 1 nM-2.5  $\mu$ M OTSSP167  $\pm$  1 nM VEN. (D) Representative plots from one donor showing gating for live CLL cells and TRAF1 expression by live CLL cells. (E) Live 623 CLL cells were gated on TRAF1<sup>lo</sup> and TRAF1<sup>hi</sup> cells for analysis of Bcl-2 and Mcl-1 expression. (F) TRAF1 624 625 expression on live CLL cells after treatment with the indicated dose of ventoclax (left) or OTSSP167 (right). 626 Graphs show %cleaved caspase- $3^+$  cells as mean±SD, n=6 (2 independent experiments pooled). 1 CLL 627 sample was from figure 4-6, 5 were new samples. Statistical analysis was performed using a non-parametric 628 Dunn's multiple comparisons test. \*p<0.05; ns, not significant. (G) Schematic showing BCR and TNFR 629 signaling pathways in CLL, with sites of action of PKN1 inhibition and venetoclax indicated.

630

Figure 1



Figure 2





Figure 4 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







